glp-1 sglt2 Complementary Yet Distinct Roles of Receptor Agonists and Inhibitors in Cardiovascular Risk Reduction GLP-1 receptor agonists and SGLT2

11.6 Evidence-Based Position Based on current literature: GLP-1 receptor agonists do not inherently cause universal nutrient depletion Intake-related vulnerability is plausible and patient-dependent Long-term micronutrient data remain limited Risk increases with magnitude and duration of weight loss Structured dietary strategy is protective Weight loss pharmacotherapy should be paired with nutritional planning

The disadvantages of oral semaglutide include: Once-daily dosing instead of once-weekly dosing for the injectable forms

Headaches are a recognised but less common side effect of GLP-1 medications

That sounds harsh

Actual solutions

Cognitive Health There is growing interest in the potential neuroprotective effects of GLP-1 receptor agonists, which could help reduce the risk of diseases like Alzheimers